Display options
Cite
Romano A, Giallongo C, La Cava P, et al. Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. Front Pharmacol. 2017;8:204doi: 10.3389/fphar.2017.00204.
Romano, A., Giallongo, C., La Cava, P., Parrinello, N. L., Chiechi, A., Vetro, C., Tibullo, D., Di Raimondo, F., Liotta, L. A., Espina, V., & Palumbo, G. A. (2017). Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. Frontiers in pharmacology, 8204. https://doi.org/10.3389/fphar.2017.00204
Romano, Alessandra, et al. "Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia." Frontiers in pharmacology vol. 8 (2017): 204. doi: https://doi.org/10.3389/fphar.2017.00204
Romano A, Giallongo C, La Cava P, Parrinello NL, Chiechi A, Vetro C, Tibullo D, Di Raimondo F, Liotta LA, Espina V, Palumbo GA. Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. Front Pharmacol. 2017 Apr 26;8:204. doi: 10.3389/fphar.2017.00204. eCollection 2017. PMID: 28491035; PMCID: PMC5405131.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2017 Apr 26;8:204. doi: 10.3389/fphar.2017.00204. eCollection 2017.

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.

Frontiers in pharmacology

Alessandra Romano, Cesarina Giallongo, Piera La Cava, Nunziatina L Parrinello, Antonella Chiechi, Calogero Vetro, Daniele Tibullo, Francesco Di Raimondo, Lance A Liotta, Virginia Espina, Giuseppe A Palumbo

Affiliations

  1. Divisione di Ematologia, Azienda Ospedaliera Policlinico UniversitariaCatania, Italy.
  2. Scuola Superiore di CataniaCatania, Italy.
  3. Center for Applied Proteomics and Molecular Medicine, George Mason UniversityManassas, VA, USA.

PMID: 28491035 PMCID: PMC5405131 DOI: 10.3389/fphar.2017.00204

Abstract

Azacytidine (5-AZA) is the standard first-choice treatment for high-risk myelodysplasia (MDS) patients. However, the clinical outcome for those patients who interrupt treatment or whose disease failed to respond is very poor. In order to identify the cellular pathways that are modified by long-term exposure to 5-AZA, we evaluated key proteins associated with the autophagy pathway by reverse-phase microarray (RPPA). Comparing bone marrow mononucleated cells (BMMCs) obtained from 20 newly-diagnosed patients and after four 5-AZA cycles we found an increased autophagy signaling. We then evaluated

Keywords: autophagy; azacytidine; myelodysplastic syndrome

References

  1. Cancer Treat Rev. 2011 Apr;37(2):160-7 - PubMed
  2. PLoS One. 2014 Jan 08;9(1):e79795 - PubMed
  3. Mol Biol Cell. 2006 May;17(5):2267-77 - PubMed
  4. Leuk Res. 2014 Jan;38(1):29-33 - PubMed
  5. Leukemia. 2015 Jul;29(7):1502-13 - PubMed
  6. Exp Hematol. 1999 Feb;27(2):229-33 - PubMed
  7. J Clin Invest. 2008 Jan;118(1):79-88 - PubMed
  8. Leuk Res. 1996 Jun;20(6):459-66 - PubMed
  9. J Leukoc Biol. 2015 Nov;98(5):769-80 - PubMed
  10. Cancer. 2011 Jun 15;117(12):2697-702 - PubMed
  11. Cell Cycle. 2011 Jun 1;10(11):1719-25 - PubMed
  12. Curr Opin Hematol. 2014 Mar;21(2):123-30 - PubMed
  13. J Biol Chem. 2008 Dec 19;283(51):35941-53 - PubMed
  14. Leukemia. 2011 Feb;25(2):271-80 - PubMed
  15. J Clin Oncol. 2011 Aug 20;29(24):3322-7 - PubMed
  16. Haematologica. 1998 Apr;83(4):358-68 - PubMed
  17. Br J Haematol. 1999 Aug;106(2):464-73 - PubMed
  18. Leukemia. 2007 Sep;21(9):1937-44 - PubMed
  19. Clin Cancer Res. 2013 May 1;19(9):2473-85 - PubMed
  20. Blood. 2007 Jul 1;110(1):313-22 - PubMed
  21. Leukemia. 2008 Jan;22(1):198-200 - PubMed
  22. Lancet Oncol. 2009 Mar;10(3):223-32 - PubMed
  23. Leuk Res. 2010 Nov;34(11):1539-42 - PubMed
  24. Blood. 1997 Mar 1;89(5):1690-700 - PubMed
  25. Leukemia. 2006 Jun;20(6):1017-27 - PubMed
  26. Leukemia. 2009 May;23(5):886-91 - PubMed
  27. Oncogene. 2016 Jan 7;35(1):1-11 - PubMed
  28. J Cell Physiol. 2009 Jun;219(3):529-34 - PubMed
  29. Biotechniques. 2012 Sep;0(0):1-7 - PubMed
  30. Autophagy. 2011 Sep;7(9):1069-70 - PubMed
  31. Leukemia. 2012 May;26(5):943-50 - PubMed
  32. N Engl J Med. 2009 Nov 5;361(19):1872-85 - PubMed
  33. Leuk Res. 2010 Dec;34(12):1576-88 - PubMed
  34. Nat Med. 2010 Aug;16(8):903-8 - PubMed
  35. Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16811-6 - PubMed
  36. J Clin Oncol. 2011 May 20;29(15):1937-8 - PubMed
  37. J Clin Invest. 2009 May;119(5):1109-23 - PubMed
  38. Leuk Res. 2015 May;39(5):501-4 - PubMed
  39. Mol Oncol. 2010 Dec;4(6):461-81 - PubMed
  40. Leuk Res. 2007 Jun;31(6):727-36 - PubMed
  41. Lancet Oncol. 2016 Apr;17(4):496-508 - PubMed
  42. Blood. 1997 Mar 15;89(6):2079-88 - PubMed
  43. Crit Rev Oncol Hematol. 2010 Dec;76(3):218-27 - PubMed
  44. Clin Cancer Res. 2012 Jun 1;18(11):3079-89 - PubMed
  45. Autophagy. 2015 ;11(7):1161-78 - PubMed
  46. J Clin Invest. 2007 Feb;117(2):326-36 - PubMed

Publication Types